MedTrace Logo

Single Dose Study With 4SC-203 in Healthy Volunteers

NCT01054937 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-01-13

No results posted yet for this study

Summary

The purpose of the study is to evaluate safety and tolerability of 4SC-203 after a single dose administration in healthy volunteers.

Conditions

Interventions

DRUG

4SC-203

i.v. administration

DRUG

Placebo

i.v. administration

Sponsors & Collaborators

  • 4SC AG

    lead INDUSTRY

Principal Investigators

  • Frank Wagner, PD Dr. med. · Charité Research Organisation GmbH, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01054937 on ClinicalTrials.gov